

Development and Applications of CRISPR-Cas9 for Genome Engineering

Patrick D. Hsu,^{1,2,3} Eric S. Lander,¹ and Feng Zhang^{1,2,*}

¹Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02141, USA

²McGovern Institute for Brain Research, Department of Brain and Cognitive Sciences, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

³Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138, USA

*Correspondence: zhang@broadinstitute.org

<http://dx.doi.org/10.1016/j.cell.2014.05.010>

Recent advances in genome engineering technologies based on the CRISPR-associated RNA-guided endonuclease Cas9 are enabling the systematic interrogation of mammalian genome function. Analogous to the search function in modern word processors, Cas9 can be guided to specific locations within complex genomes by a short RNA search string. Using this system, DNA sequences within the endogenous genome and their functional outputs are now easily edited or modulated in virtually any organism of choice. Cas9-mediated genetic perturbation is simple and scalable, empowering researchers to elucidate the functional organization of the genome at the systems level and establish causal linkages between genetic variations and biological phenotypes. In this Review, we describe the development and applications of Cas9 for a variety of research or translational applications while highlighting challenges as well as future directions. Derived from a remarkable microbial defense system, Cas9 is driving innovative applications from basic biology to biotechnology and medicine.

Introduction

The development of recombinant DNA technology in the 1970s marked the beginning of a new era for biology. For the first time, molecular biologists gained the ability to manipulate DNA molecules, making it possible to study genes and harness them to develop novel medicine and biotechnology. Recent advances in genome engineering technologies are sparking a new revolution in biological research. Rather than studying DNA taken out of the context of the genome, researchers can now directly edit or modulate the function of DNA sequences in their endogenous context in virtually any organism of choice, enabling them to elucidate the functional organization of the genome at the systems level, as well as identify causal genetic variations.

Broadly speaking, genome engineering refers to the process of making targeted modifications to the genome, its contexts (e.g., epigenetic marks), or its outputs (e.g., transcripts). The ability to do so easily and efficiently in eukaryotic and especially mammalian cells holds immense promise to transform basic science, biotechnology, and medicine (Figure 1).

For life sciences research, technologies that can delete, insert, and modify the DNA sequences of cells or organisms enable dissecting the function of specific genes and regulatory elements. Multiplexed editing could further allow the interrogation of gene or protein networks at a larger scale. Similarly, manipulating transcriptional regulation or chromatin states at particular loci can reveal how genetic material is organized and utilized within a cell, illuminating relationships between the architecture

of the genome and its functions. In biotechnology, precise manipulation of genetic building blocks and regulatory machinery also facilitates the reverse engineering or reconstruction of useful biological systems, for example, by enhancing biofuel production pathways in industrially relevant organisms or by creating infection-resistant crops. Additionally, genome engineering is stimulating a new generation of drug development processes and medical therapeutics. Perturbation of multiple genes simultaneously could model the additive effects that underlie complex polygenic disorders, leading to new drug targets, while genome editing could directly correct harmful mutations in the context of human gene therapy (Tebas et al., 2014).

Eukaryotic genomes contain billions of DNA bases and are difficult to manipulate. One of the breakthroughs in genome manipulation has been the development of gene targeting by homologous recombination (HR), which integrates exogenous repair templates that contain sequence homology to the donor site (Figure 2A) (Capecchi, 1989). HR-mediated targeting has facilitated the generation of knockin and knockout animal models via manipulation of germline competent stem cells, dramatically advancing many areas of biological research. However, although HR-mediated gene targeting produces highly precise alterations, the desired recombination events occur extremely infrequently (1 in 10^6 – 10^9 cells) (Capecchi, 1989), presenting enormous challenges for large-scale applications of gene-targeting experiments.

To overcome these challenges, a series of programmable nuclease-based genome editing technologies have been




Figure 1. Applications of Genome Engineering

Genetic and epigenetic control of cells with genome engineering technologies is enabling a broad range of applications from basic biology to biotechnology and medicine. (Clockwise from top) Causal genetic mutations or epigenetic variants associated with altered biological function or disease phenotypes can now be rapidly and efficiently recapitulated in animal or cellular models (Animal models, Genetic variation). Manipulating biological circuits could also facilitate the generation of useful synthetic materials, such as algae-derived, silica-based diatoms for oral drug delivery (Materials). Additionally, precise genetic engineering of important agricultural crops could confer resistance to environmental deprivation or pathogenic infection, improving food security while avoiding the introduction of foreign DNA (Food). Sustainable and cost-effective biofuels are attractive sources for renewable energy, which could be achieved by creating efficient metabolic pathways for ethanol production in algae or corn (Fuel). Direct in vivo correction of genetic or epigenetic defects in somatic tissue would be permanent genetic solutions that address the root cause of genetically encoded disorders (Gene surgery). Finally, engineering cells to optimize high yield generation of drug precursors in bacterial factories could significantly reduce the cost and accessibility of useful therapeutics (Drug development).

developed in recent years, enabling targeted and efficient modification of a variety of eukaryotic and particularly mammalian species. Of the current generation of genome editing technologies, the most rapidly developing is the class of RNA-guided endonucleases known as Cas9 from the microbial adaptive immune system CRISPR (clustered regularly interspaced short palindromic repeats), which can be easily targeted to virtually any genomic location of choice by a short RNA guide. Here, we review the development and applications of the CRISPR-associated endonuclease Cas9 as a platform technology for achieving targeted perturbation of endogenous genomic elements and also discuss challenges and future avenues for innovation.

Programmable Nucleases as Tools for Efficient and Precise Genome Editing

A series of studies by Haber and Jasin (Rudin et al., 1989; Plessis et al., 1992; Rouet et al., 1994; Choulika et al., 1995; Bibikova et al., 2001; Bibikova et al., 2003) led to the realization that tar-

geted DNA double-strand breaks (DSBs) could greatly stimulate genome editing through HR-mediated recombination events. Subsequently, Carroll and Chandrasegaran demonstrated the potential of designer nucleases based on zinc finger proteins for efficient, locus-specific HR (Bibikova et al., 2001, 2003). Moreover, it was shown in the absence of an exogenous homology repair template that localized DSBs can induce insertions or deletion mutations (indels) via the error-prone nonhomologous end-joining (NHEJ) repair pathway (Figure 2A) (Bibikova et al., 2002). These early genome editing studies established DSB-induced HR and NHEJ as powerful pathways for the versatile and precise modification of eukaryotic genomes.

To achieve effective genome editing via introduction of site-specific DNA DSBs, four major classes of customizable DNA-binding proteins have been engineered so far: meganucleases derived from microbial mobile genetic elements (Smith et al., 2006), zinc finger (ZF) nucleases based on eukaryotic transcription factors (Urnov et al., 2005; Miller et al., 2007), transcription activator-like effectors (TALEs) from *Xanthomonas* bacteria (Christian et al., 2010; Miller et al., 2011; Boch et al., 2009; Moscou and Bogdanove, 2009), and most recently the RNA-guided DNA endonuclease Cas9 from the type II bacterial adaptive immune system CRISPR (Cong et al., 2013; Mali et al., 2013a).

Meganuclease, ZF, and TALE proteins all recognize specific DNA sequences through protein-DNA interactions. Although meganucleases integrate its nuclease and DNA-binding domains, ZF and TALE proteins consist of individual modules targeting 3 or 1 nucleotides (nt) of DNA, respectively (Figure 2B). ZFs and TALEs can be assembled in desired combinations and attached to the nuclease domain of FokI to direct nucleolytic activity toward specific genomic loci. Each of these platforms, however, has unique limitations.

Meganucleases have not been widely adopted as a genome engineering platform due to lack of clear correspondence between meganuclease protein residues and their target DNA sequence specificity. ZF domains, on the other hand, exhibit context-dependent binding preference due to crosstalk between adjacent modules when assembled into a larger array (Maeder et al., 2008). Although multiple strategies have been developed to account for these limitations (Gonzalez et al., 2010; Sander et al., 2011), assembly of functional ZFPs with the desired DNA binding specificity remains a major challenge that requires an extensive screening process. Similarly, although TALE DNA-binding monomers are for the most part modular, they can still suffer from context-dependent specificity (Juillerat et al., 2014), and their repetitive sequences render construction of novel TALE arrays labor intensive and costly.

Given the challenges associated with engineering of modular DNA-binding proteins, new modes of recognition would significantly simplify the development of custom nucleases. The CRISPR nuclease Cas9 is targeted by a short guide RNA that recognizes the target DNA via Watson-Crick base pairing (Figure 2C). The guide sequence within these CRISPR RNAs typically corresponds to phage sequences, constituting the natural mechanism for CRISPR antiviral defense, but can be easily replaced by a sequence of interest to retarget the Cas9 nuclease. Multiplexed targeting by Cas9 can now be achieved at unprecedented scale by introducing a battery of short guide




Figure 2. Genome Editing Technologies Exploit Endogenous DNA Repair Machinery

(A) DNA double-strand breaks (DSBs) are typically repaired by nonhomologous end-joining (NHEJ) or homology-directed repair (HDR). In the error-prone NHEJ pathway, Ku heterodimers bind to DSB ends and serve as a molecular scaffold for associated repair proteins. Indels are introduced when the complementary strands undergo end resection and misaligned repair due to microhomology, eventually leading to frameshift mutations and gene knockout. Alternatively, Rad51 proteins may bind DSB ends during the initial phase of HDR, recruiting accessory factors that direct genomic recombination with homology arms on an exogenous repair template. Bypassing the matching sister chromatid facilitates the introduction of precise gene modifications.

(B) Zinc finger (ZF) proteins and transcription activator-like effectors (TALEs) are naturally occurring DNA-binding domains that can be modularly assembled to target specific sequences. ZF and TALE domains each recognize 3 and 1 bp of DNA, respectively. Such DNA-binding proteins can be fused to the FokI endonuclease to generate programmable site-specific nucleases. (C) The Cas9 nuclease from the microbial CRISPR adaptive immune system is localized to specific DNA sequences via the guide sequence on its guide RNA (red), directly base-pairing with the DNA target. Binding of a protospacer-adjacent motif (PAM, blue) downstream of the target locus helps to direct Cas9-mediated DSBs.

RNAs rather than a library of large, bulky proteins. The ease of Cas9 targeting, its high efficiency as a site-specific nuclease, and the possibility for highly multiplexed modifications have opened up a broad range of biological applications across basic research to biotechnology and medicine.

The utility of customizable DNA-binding domains extends far beyond genome editing with site-specific endonucleases. Fusing them to modular, sequence-agnostic functional effector domains allows flexible recruitment of desired perturbations, such as transcriptional activation, to a locus of interest (Xu and Bestor, 1997; Beerli et al., 2000a; Konermann et al., 2013; Maeder et al., 2013a; Mendenhall et al., 2013). In fact, any modular enzymatic component can, in principle, be substituted, allowing facile additions to the genome engineering toolbox. Integration of genome- and epigenome-modifying enzymes with inducible protein regulation further allows precise temporal control of dynamic processes (Beerli et al., 2000b; Konermann et al., 2013).

CRISPR-Cas9: From Yogurt to Genome Editing

The recent development of the Cas9 endonuclease for genome editing draws upon more than a decade of basic research into understanding the biological function of the mysterious repetitive elements now known as CRISPR (Figure 3), which are found throughout the bacterial and archaeal diversity. CRISPR loci typically consist of a clustered set of CRISPR-associated (Cas) genes and the signature CRISPR array—a series of repeat sequences (direct repeats) interspaced by variable sequences (spacers) corresponding to sequences within foreign genetic elements (protospacers) (Figure 4). Whereas Cas genes are translated into proteins, most CRISPR arrays are first tran-

scribed as a single RNA before subsequent processing into shorter CRISPR RNAs (crRNAs), which direct the nucleolytic activity of certain Cas enzymes to degrade target nucleic acids.

The CRISPR story began in 1987. While studying the *iap* gene involved in isozyme conversion of alkaline phosphatase in *E. coli*, Nakata and colleagues reported a curious set of 29 nt repeats downstream of the *iap* gene (Ishino et al., 1987). Unlike most repetitive elements, which typically take the form of tandem repeats like TALE repeat monomers, these 29 nt repeats were interspaced by five intervening 32 nt nonrepetitive sequences. Over the next 10 years, as more microbial genomes were sequenced, additional repeat elements were reported from genomes of different bacterial and archaeal strains. Mojica and colleagues eventually classified interspaced repeat sequences as a unique family of clustered repeat elements present in >40% of sequenced bacteria and 90% of archaea (Mojica et al., 2000).

These early findings began to stimulate interest in such microbial repeat elements. By 2002, Jansen and Mojica coined the acronym CRISPR to unify the description of microbial genomic loci consisting of an interspaced repeat array (Jansen et al., 2002; Barrangou and van der Oost, 2013). At the same time, several clusters of signature CRISPR-associated (cas) genes were identified to be well conserved and typically adjacent to the repeat elements (Jansen et al., 2002), serving as a basis for the eventual classification of three different types of CRISPR systems (types I–III) (Haft et al., 2005; Makarova et al., 2011b). Types I and III CRISPR loci contain multiple Cas proteins, now known to form complexes with crRNA (CASCADE complex for type I; Cmr or Csm RAMP complexes for type III) to facilitate the recognition and destruction of target nucleic acids (Brouns




Figure 3. Key Studies Characterizing and Engineering CRISPR Systems

Cas9 has also been referred to as Cas5, Csx12, and Csn1 in literature prior to 2012. For clarity, we exclusively adopt the Cas9 nomenclature throughout this Review. CRISPR, clustered regularly interspaced short palindromic repeats; Cas, CRISPR-associated; crRNA, CRISPR RNA; DSB, double-strand break; tracrRNA, *trans*-activating CRISPR RNA.

et al., 2008; Hale et al., 2009) (Figure 4). In contrast, the type II system has a significantly reduced number of Cas proteins. However, despite increasingly detailed mapping and annotation of CRISPR loci across many microbial species, their biological significance remained elusive.

A key turning point came in 2005, when systematic analysis of the spacer sequences separating the individual direct repeats suggested their extrachromosomal and phage-associated origins (Mojica et al., 2005; Pourcel et al., 2005; Bolotin et al., 2005). This insight was tremendously exciting, especially given previous studies showing that CRISPR loci are transcribed (Tang et al., 2002) and that viruses are unable to infect archaeal cells carrying spacers corresponding to their own genomes (Mojica et al., 2005). Together, these findings led to the speculation that CRISPR arrays serve as an immune memory and defense mechanism, and individual spacers facilitate defense against bacteriophage infection by exploiting Watson-Crick base-pairing between nucleic acids (Mojica et al., 2005; Pourcel et al., 2005). Despite these compelling realizations that CRISPR loci might be involved in microbial immunity, the specific mechanism of how the spacers act to mediate viral defense remained a challenging puzzle. Several hypotheses were raised, including thoughts that CRISPR spacers act as small RNA guides to

degrade viral transcripts in a RNAi-like mechanism (Makarova et al., 2006) or that CRISPR spacers direct Cas enzymes to cleave viral DNA at spacer-matching regions (Bolotin et al., 2005).

Working with the dairy production bacterial strain *Streptococcus thermophilus* at the food ingredient company Danisco, Horvath and colleagues uncovered the first experimental evidence for the natural role of a type II CRISPR system as an adaptive immunity system, demonstrating a nucleic-acid-based immune system in which CRISPR spacers dictate target specificity while Cas enzymes control spacer acquisition and phage defense (Barrangou et al., 2007). A rapid series of studies illuminating the mechanisms of CRISPR defense followed shortly and helped to establish the mechanism as well as function of all three types of CRISPR loci in adaptive immunity. By studying the type I CRISPR locus of *Escherichia coli*, van der Oost and colleagues showed that CRISPR arrays are transcribed and converted into small crRNAs containing individual spacers to guide Cas nuclease activity (Brouns et al., 2008). In the same year, CRISPR-mediated defense by a type III-A CRISPR system from *Staphylococcus epidermidis* was demonstrated to block plasmid conjugation, establishing the target of Cas enzyme activity as DNA rather than RNA (Marraffini and Sontheimer,




Figure 4. Natural Mechanisms of Microbial CRISPR Systems in Adaptive Immunity

Following invasion of the cell by foreign genetic elements from bacteriophages or plasmids (step 1: phage infection), certain CRISPR-associated (Cas) enzymes acquire spacers from the exogenous protospacer sequences and install them into the CRISPR locus within the prokaryotic genome (step 2: spacer acquisition). These spacers are segregated between direct repeats that allow the CRISPR system to mediate self and nonself recognition. The CRISPR array is a noncoding RNA transcript that is enzymatically matured through distinct pathways that are unique to each type of CRISPR system (step 3: crRNA biogenesis and processing).

In types I and III CRISPR, the pre-crRNA transcript is cleaved within the repeats by CRISPR-associated ribonucleases, releasing multiple small crRNAs. Type III crRNA intermediates are further processed at the 3' end by yet-to-be-identified RNases to produce the fully mature transcript. In type II CRISPR, an associated *trans*-activating CRISPR RNA (tracrRNA) hybridizes with the direct repeats, forming an RNA duplex that is cleaved and processed by endogenous RNase III and other unknown nucleases. Matured crRNAs from type I and III CRISPR systems are then loaded onto effector protein complexes for target recognition and degradation. In type II systems, crRNA-tracrRNA hybrids complex with Cas9 to mediate interference.

Both type I and III CRISPR systems use multi-protein interference modules to facilitate target recognition. In type I CRISPR, the Cascade complex is loaded with a crRNA molecule, constituting a catalytically inert surveillance complex that recognizes target DNA. The Cas3 nuclease is then recruited to the Cascade-bound R loop, mediating target degradation. In type III CRISPR, crRNAs associate either with Csm or Cmr complexes that bind and cleave DNA and RNA substrates, respectively. In contrast, the type II system requires only the Cas9 nuclease to degrade DNA matching its dual guide RNA consisting of a crRNA-tracrRNA hybrid.

2008), although later investigation of a different type III-B system from *Pyrococcus furiosus* also revealed crRNA-directed RNA cleavage activity (Hale et al., 2009, 2012).

As the pace of CRISPR research accelerated, researchers quickly unraveled many details of each type of CRISPR system (Figure 4). Building on an earlier speculation that protospacer-adjacent motifs (PAMs) may direct the type II Cas9 nuclease to cleave DNA (Bolotin et al., 2005), Moineau and colleagues highlighted the importance of PAM sequences by demonstrating that PAM mutations in phage genomes circumvented CRISPR interference (Deveau et al., 2008). Additionally, for types I and II, the lack of PAM within the direct repeat sequence within the CRISPR array prevents self-targeting by the CRISPR system. In type III systems, however, mismatches between the 5' end of the crRNA and the DNA target are required for plasmid interference (Marrafini and Sontheimer, 2010).

By 2010, just 3 years after the first experimental evidence for CRISPR in bacterial immunity, the basic function and mechanisms of CRISPR systems were becoming clear. A variety of groups had begun to harness the natural CRISPR system for various biotechnological applications, including the generation of phage-resistant dairy cultures (Quiberoni et al., 2010) and phylogenetic classification of bacterial strains (Horvath et al., 2008, 2009). However, genome editing applications had not yet been explored.

Around this time, two studies characterizing the functional mechanisms of the native type II CRISPR system elucidated the basic components that proved vital for engineering a simple RNA-programmable DNA endonuclease for genome editing. First, Moineau and colleagues used genetic studies in *Streptococcus thermophilus* to reveal that Cas9 (formerly called Cas5, Csn1, or Csx12) is the only enzyme within the cas gene cluster that mediates target DNA cleavage (Garneau et al., 2010). Next, Charpentier and colleagues revealed a key component in the biogenesis and processing of crRNA in type II CRISPR systems—a noncoding *trans*-activating crRNA (tracrRNA) that hybridizes with crRNA to facilitate RNA-guided targeting of Cas9 (Deltcheva et al., 2011). This dual RNA hybrid, together with Cas9 and endogenous RNase III, is required for processing the CRISPR array transcript into mature crRNAs (Deltcheva et al., 2011). These two studies suggested that there are at least three components (Cas9, the mature crRNA, and tracrRNA) that are essential for reconstituting the type II CRISPR nuclease system. Given the increasing importance of programmable site-specific nucleases based on ZFs and TALEs for enhancing eukaryotic genome editing, it was tantalizing to think that perhaps Cas9 could be developed into an RNA-guided genome editing system. From this point, the race to harness Cas9 for genome editing was on.

In 2011, Siksnys and colleagues first demonstrated that the type II CRISPR system is transferable, in that transplantation of the type II CRISPR locus from *Streptococcus thermophilus* into *Escherichia coli* is able to reconstitute CRISPR interference in a different bacterial strain (Sapranaukas et al., 2011). By 2012, biochemical characterizations by the groups of Charpentier, Doudna, and Siksnys showed that purified Cas9 from *Streptococcus thermophilus* or *Streptococcus pyogenes* can be guided by crRNAs to cleave target DNA in vitro (Jinek et al., 2012; Gasiunas et al., 2012), in agreement with previous bacterial studies (Garneau et al., 2010; Deltcheva et al., 2011; Sapranaukas et al., 2011). Furthermore, a single guide RNA (sgRNA) can be constructed by fusing a crRNA containing the targeting guide sequence to a tracrRNA that facilitates DNA cleavage by Cas9 in vitro (Jinek et al., 2012).

In 2013, a pair of studies simultaneously showed how to successfully engineer type II CRISPR systems from *Streptococcus thermophilus* (Cong et al., 2013) and *Streptococcus pyogenes* (Cong et al., 2013; Mali et al., 2013a) to accomplish genome editing in mammalian cells. Heterologous expression of mature crRNA-tracrRNA hybrids (Cong et al., 2013) as well as sgRNAs (Cong et al., 2013; Mali et al., 2013a) directs Cas9 cleavage within the mammalian cellular genome to stimulate NHEJ or HDR-mediated genome editing. Multiple guide RNAs can also be used to target several genes at once. Since these initial studies, Cas9 has been used by thousands of laboratories for genome editing applications in a variety of experimental model systems (Sander and Joung, 2014). The rapid adoption of the Cas9 technology was also greatly accelerated through a combination of open-source distributors such as Addgene, as well as a number of online user forums such as <http://www.genome-engineering.org> and <http://www.egenome.org>.

Structural Organization and Domain Architecture of Cas9

The family of Cas9 proteins is characterized by two signature nuclease domains, RuvC and HNH, each named based on homology to known nuclease domain structures (Figure 2C). Though HNH is a single nuclease domain, the full RuvC domain is divided into three subdomains across the linear protein sequence, with RuvC I near the N-terminal region of Cas9 and RuvC II/III flanking the HNH domain near the middle of the protein. Recently, a pair of structural studies shed light on the structural mechanism of RNA-guided DNA cleavage by Cas9.

First, single-particle EM reconstructions of the *Streptococcus pyogenes* Cas9 (SpCas9) revealed a large structural rearrangement between apo-Cas9 unbound to nucleic acid and Cas9 in complex with crRNA and tracrRNA, forming a central channel to accommodate the RNA-DNA heteroduplex (Jinek et al., 2014). Second, a high-resolution structure of SpCas9 in complex with sgRNA and the complementary strand of target DNA further revealed the domain organization to comprise of an α -helical recognition (REC) lobe and a nuclease (NUC) lobe consisting of the HNH domain, assembled RuvC subdomains, and a PAM-interacting (PI) C-terminal region (Nishimasu et al., 2014) (Figure 5A and Movie S1).

Together, these two studies support the model that SpCas9 unbound to target DNA or guide RNA exhibits an autoinhibited

conformation in which the HNH domain active site is blocked by the RuvC domain and is positioned away from the REC lobe (Jinek et al., 2014). Binding of the RNA-DNA heteroduplex would additionally be sterically inhibited by the orientation of the C-terminal domain. As a result, apo-Cas9 likely cannot bind nor cleave target DNA. Like many ribonucleoprotein complexes, the guide RNA serves as a scaffold around which Cas9 can fold and organize its various domains (Nishimasu et al., 2014).

The crystal structure of SpCas9 in complex with an sgRNA and target DNA also revealed how the REC lobe facilitates target binding. An arginine-rich bridge helix (BH) within the REC lobe is responsible for contacting the 3' 8–12 nt of the RNA-DNA heteroduplex (Nishimasu et al., 2014), which correspond with the seed sequence identified through guide sequence mutation experiments (Jinek et al., 2012; Cong et al., 2013; Fu et al., 2013; Hsu et al., 2013; Pattanayak et al., 2013; Mali et al., 2013b).

The SpCas9 structure also provides a useful scaffold for engineering or refactoring of Cas9 and sgRNA. Because the REC2 domain of SpCas9 is poorly conserved in shorter orthologs, domain recombination or truncation is a promising approach for minimizing Cas9 size. SpCas9 mutants lacking REC2 retain roughly 50% of wild-type cleavage activity, which could be partly attributed to their weaker expression levels (Nishimasu et al., 2014). Introducing combinations of orthologous domain recombination, truncation, and peptide linkers could facilitate the generation of a suite of Cas9 mutant variants optimized for different parameters such as DNA binding, DNA cleavage, or overall protein size.

Metagenomic, Structural, and Functional Diversity of Cas9

Cas9 is exclusively associated with the type II CRISPR locus and serves as the signature type II gene. Based on the diversity of associated Cas genes, type II CRISPR loci are further subdivided into three subtypes (IIA–IIC) (Figure 5B) (Makarova et al., 2011a; Chylinski et al., 2013). Type II CRISPR loci mostly consist of the *cas9*, *cas1*, and *cas2* genes, as well as a CRISPR array and tracrRNA. Type IIC CRISPR systems contain only this minimal set of cas genes, whereas types IIA and IIB have an additional signature *csn2* or *cas4* gene, respectively (Chylinski et al., 2013).

Subtype classification of type II CRISPR loci is based on the architecture and organization of each CRISPR locus. For example, type IIA and IIB loci usually consist of four *cas* genes, whereas type IIC loci only contain three *cas* genes. However, this classification does not reflect the structural diversity of Cas9 proteins, which exhibit sequence homology and length variability irrespective of the subtype classification of their parental CRISPR locus. Of >1,000 Cas9 nucleases identified from sequence databases (UniProt) based on homology, protein length is rather heterogeneous, roughly ranging from 900 to 1600 amino acids (Figure 5C). The length distribution of most Cas9 proteins can be divided into two populations centered around 1,100 and 1,350 amino acids in length. It is worth noting that a third population of large Cas9 proteins belonging to subtype IIA, formerly called Csx12, typically contain around 1500 amino acids.

Despite the apparent diversity of protein length, all Cas9 proteins share similar domain architecture (Makarova et al., 2011a;




Figure 5. Structural and Metagenomic Diversity of Cas9 Orthologs

(A) Crystal structure of *Streptococcus pyogenes* Cas9 in complex with guide RNA and target DNA.

(B) Canonical CRISPR locus organization from type II CRISPR systems, which can be classified into IIA-IIC based on their *cas* gene clusters. Whereas type IIC CRISPR loci contain the minimal set of *cas9*, *cas1*, and *cas2*, IIA and IIB retain their signature *csn2* and *cas4* genes, respectively.

(C) Histogram displaying length distribution of known Cas9 orthologs as described in UniProt, HAMAP protein family profile MF_01480.

(D) Phylogenetic tree displaying the microbial origin of Cas9 nucleases from the type II CRISPR immune system. Taxonomic information was derived from greengenes 16S rRNA gene sequence alignment, and the tree was visualized using the Interactive Tree of Life tool (iTol).

(E) Four Cas9 orthologs from families IIA, IIB, and IIC were aligned by ClustalW (BLOSUM). Domain alignment is based on the *Streptococcus pyogenes* Cas9, whereas residues highlighted in red indicate highly conserved catalytic residues within the RuvC I and HNH nuclease domains.

Chylinski et al., 2013, 2014; Fonfara et al., 2014), consisting of the RuvC and HNH nuclease domains and the REC domain, an α -helix-rich region with an Arg-rich bridge helix. Unlike type I and III CRISPR systems, which are found in both bacteria and archaea, type II CRISPRs have so far only been found in bacterial strains (Chylinski et al., 2013). The majority of Cas9 orthologs in fact belong to the phyla of *Bacteroidetes*, *Proteobacteria*, and *Firmicutes* (Figure 5D).

The length difference among Cas9 proteins largely results from variable conservation of the REC domain (Figure 5E), which associates with the sgRNA and target DNA. For example, the type IIC *Actinomyces naeslundii* Cas9, which is more compact than its *Streptococcus pyogenes* ortholog, has a much smaller REC lobe with substantially different orientation (Jinek et al., 2014).

Protospacer Adjacent Motif: Cas9 Target Range and Search Mechanism

A critical feature of the Cas9 system is the protospacer-adjacent motif (PAM), which flanks the 3' end of the DNA target site (Figure 2C) and dictates the DNA target search mechanism of Cas9. In addition to facilitating self versus non-self discrimination by Cas9 (Shah et al., 2013), because direct repeats do not contain PAM sites, biochemical and structural characterization of SpCas9 suggested that PAM recognition is involved in triggering the transition between Cas9 target binding and cleavage conformations (Sternberg et al., 2014; Jinek et al., 2014; Nishimasu et al., 2014).

Single-molecule imaging indicated that Cas9-crRNA-tracrRNA complexes first associate with PAM sequences throughout the genome, allowing Cas9 to initiate DNA strand separation via unknown mechanisms (Sternberg et al., 2014). DNA competitor cleavage assays additionally suggested that formation of the RNA-DNA heteroduplex is initiated at the PAM site before proceeding PAM distally by interrogating the target site upstream of the PAM for guide sequence complementarity (Sternberg et al., 2014). Binding of the PAM and a matching target then triggers Cas9 nuclease activity by activating the HNH and RuvC domains, supported by the observation of HNH domain flexibility within the Cas9-sgRNA-DNA ternary complex (Nishimasu et al., 2014).

The complexity of the PAM sequences also determines the overall DNA targeting space of Cas9. For example, the 5'-NGG of SpCas9 allows it to target, on average, every 8 bp within the human genome (Cong et al., 2013; Hsu et al., 2013). Additionally, SpCas9 can target sites flanked by 5'-NAG PAMs (Jiang et al., 2013; Hsu et al., 2013), albeit at a lower efficiency, further expanding its editing versatility. The PAM is specific to each Cas9 ortholog, even within the same species, such as 5'-NNA GAAW for *Streptococcus thermophilus* CRISPR1 (Deveau et al., 2008) and 5'-NGGNG for *Streptococcus thermophilus* CRISPR3 (Horvath et al., 2008). Another Cas9 from *Neisseria meningitidis* with a 5'-NNNGATT PAM requirement (Zhang et al., 2013) was recently applied in human pluripotent stem cells (Hou et al., 2013).

Computational (Chylinski et al., 2013, 2014; Fonfara et al., 2014) or metagenomic analysis of bacteria and archaea containing CRISPR loci could lead to the discovery of Cas9 nucleases

with additional PAMs to expand the targeting range of the Cas9 toolkit. Delivery of multiple Cas9 proteins with different PAM requirements facilitates orthogonal genome engineering, in which independent but simultaneous functions are applied at different loci within the same cell or cell population. NmCas9 and SpCas9, for example, can be employed for independent transcriptional repression and nuclease activity (Esvelt et al., 2013).

PAM specificity can also be modified. For instance, orthologous replacement of the PAM-interacting (PI) domain from the *Streptococcus thermophilus* CRISPR3 Cas9 with the corresponding domain from *Streptococcus pyogenes* Cas9 successfully altered PAM recognition from 5'-NGGNG to 5'-NGG (Nishimasu et al., 2014). PAM engineering strategies could also be exploited to generate short Cas9 orthologs with flexible 5'-NGG or 5'-NG PAM domains.

Genome Editing Using CRISPR-Cas9 in Eukaryotic Cells

To date, the *Streptococcus pyogenes* Cas9 (SpCas9) has been used broadly to achieve efficient genome editing in a variety of species and cell types, including human cell lines, bacteria, zebrafish, yeast, mouse, fruit fly, roundworm, rat, common crops, pig, and monkey (see Sander and Joung [2014] for a detailed list). SpCas9 is also dramatically expanding the catalog of genetically tractable model organisms, for example, by enabling the introduction of multiplex mutations in cynomolgus monkeys (Niu et al., 2014).

SpCas9 can be targeted either with a pair of crRNA and tracrRNA (Cong et al., 2013) or with a chimeric sgRNA (Cong et al., 2013; Mali et al., 2013a; Cho et al., 2013; Jinek et al., 2013), as the crRNA or sgRNA contains a 20 nt guide sequence that directly matches the target site. The only requirement for the selection of Cas9 target sites is the presence of a protospacer-adjacent motif (PAM) immediately downstream of the target site.

An early discrepancy in the use of SpCas9 editing of the human genome was the drastically higher levels of NHEJ-induced indels given the same target site, when using the engineered dual guide RNA system (Cong et al., 2013) compared to the engineered sgRNA(+48) scaffold, which only contained up to the 48th base of tracrRNA. Although sgRNA(+48) is sufficient for cleaving DNA in vitro (Jinek et al., 2012), extension of the 3' tracrRNA sequence preserved several hairpin structures (sgRNA(+72) and sgRNA(+84)) that were critical for effective sgRNA-mediated genome editing in vivo (Mali et al., 2013a; Hsu et al., 2013). The additional stem loops enhance the stability of the sgRNA (Hsu et al., 2013) and are important for proper Cas9-sgRNA-DNA ternary complex formation (Nishimasu et al., 2014). These analyses of the sgRNA structure and function indicate that careful sgRNA design is critical for optimal Cas9 activity, especially for testing novel Cas9 candidates derived from metagenomic analysis.

One hallmark of the natural CRISPR-Cas9 system is its inherent ability to efficiently cleave multiple distinct target sequences in parallel (Barrangou et al., 2007; Garneau et al., 2010) by converting a pre-crRNA transcript containing many spacers into individual guide RNAs duplexes (mature crRNA and tracrRNA) through hybridization with tracrRNA (Deltcheva et al., 2011). Harnessing this unique aspect of CRISPR

interference would enable highly scalable multiplex perturbations. Indeed, coexpression of a CRISPR array containing spacers targeting different genes (Cong et al., 2013) or a battery of several sgRNAs (Mali et al., 2013a; Wang et al., 2013) together with SpCas9 has led to efficient multiplex editing in mammalian cells. Surprisingly, CRISPR arrays containing direct repeats interspaced by designer spacers were processed into mature guide RNAs without the introduction of bacterial RNase III. Because RNase III is required for crRNA maturation in prokaryotic cells (Deltcheva et al., 2011), it is likely that endogenous mammalian RNases play compensatory roles (Cong et al., 2013).

Specificity of Cas9 Nucleases

Because genome editing leads to permanent modifications within the genome, the targeting specificity of Cas9 nucleases is of particular concern, especially for clinical applications and gene therapy. A combination of in vitro and in vivo assays has been typically used to characterize the specificity of ZFNs and TALENs (Gabriel et al., 2011), but systematic analysis has remained challenging due to difficulties in synthesizing large libraries of proteins with varying sequence specificity. However, Cas9 target recognition is dictated by the Watson-Crick base-pairing interactions of an RNA guide with its DNA target, enabling experimentally tractable and systematic evaluation of the effect of guide RNA-target DNA mismatches on Cas9 activity.

Streptococcus pyogenes Cas9 specificity has been extensively characterized by multiple groups using mismatched guide RNA libraries, in vitro selection, and reporter assays (Fu et al., 2013; Hsu et al., 2013; Mali et al., 2013b; Pattanayak et al., 2013). In contrast to previous studies that suggested a seed sequence model for Cas9 specificity, wherein the first 8–12 PAM-proximal guide sequence bases determine specificity (Jinek et al., 2012; Cong et al., 2013), these studies collectively demonstrate that Cas9 tolerates mismatches throughout the guide sequence in a manner that is sensitive to the number, position, and distribution of the mismatches (Fu et al., 2013; Hsu et al., 2013; Mali et al., 2013b; Pattanayak et al., 2013). Although the PAM-distal bases of the guide sequence are less important for specificity, meaning that mismatches at those positions often do not abolish Cas9 activity, all positions within the guide contribute to overall specificity. Importantly, off-target sites followed by the 5'-NAG PAM can also lead to off-target cleavage, demonstrating the importance of considering both NGG and NAG PAMs in off-target analysis.

Interestingly, Cas9 requires extensive homology between the guide RNA and target DNA in order to cleave but can remain semi-transiently bound with only a short stretch of complementary sequence between the guide RNA and target DNA. These observations suggest that Cas9 has many off-target binding sites but cleaves only a small fraction of them (Wu et al., 2014). Thus, concerns about off-target activity could vary widely given a desired application that exploits Cas9 for its DNA binding or cleavage capabilities.

Enzymatic concentration is also an important factor in determining Cas9 off-target mutagenesis. This is particularly important because Cas9 can tolerate even five mismatches within the target site (Fu et al., 2013). Mismatches appear to be better tolerated when Cas9 is present at high concentrations (Hsu

et al., 2013; Pattanayak et al., 2013), leading to higher off-target activity; decreasing Cas9 concentration significantly improves the on- to off-target ratio at the expense of the efficiency of on-target cleavage (Hsu et al., 2013). The duration of Cas9 expression is likely an additional factor that tunes off-target activity, though its contributions remain to be carefully investigated.

While potential off-target sites have typically been computationally determined by searching for genomic sequences with high sequence similarity to the desired target locus, whole-genome sequencing or other unbiased ways of labeling DNA DSBs genome-wide may illuminate off-target sites that are not predictable by first-order sequence comparison. Unbiased genome-wide characterizations have been previously used to characterize ZFN off-target mutagenesis (Gabriel et al., 2011) and could easily be adapted for Cas9 nuclease activity. Such data, perhaps in combination with thermodynamic characterization of guide RNA and target DNA hybridization, will likely provide a quantitative framework for assessing and predicting the off-target activity of Cas9. Multiple groups now provide Cas9 target selection tools (e.g., <http://tools.genome-engineering.org>, <http://zifit.partners.org>, and <http://www.e-crisp.org>).

Improving Cas9 Target Recognition Fidelity

Cas9 nucleases cleave DNA through the activity of their RuvC and HNH nuclease domains, each of which nicks a strand of DNA to generate a blunt-ended DSB (Figure 2C). SpCas9 can be converted into a DNA “nickase” that creates a single-stranded break (SSB) by catalytically inactivating the RuvC or HNH nuclease domains (Gasiunas et al., 2012; Jinek et al., 2012; Sapranaukas et al., 2011) via point mutations (Figure 6A). Because DNA single-strand breaks are repaired via the high-fidelity base excision repair (BER) pathway (Dianov and Hübscher, 2013), Cas9 nickases can be exploited for more specific NHEJ as well as HR.

To improve on-target DSB specificity, a double-nicking approach analogous to dimeric ZFNs or TALENs can be used to increase the overall number of bases that are specifically recognized in the target DNA. Using pairs of guide RNAs (Mali et al., 2013b; Ran et al., 2013) and an SpCas9 HNH⁺/RuvC[−] nickase mutant (D10A), properly spaced cooperative nicks can mimic DSBs and mediate efficient indel formation (Figure 6B). Because off-target nick sites are precisely repaired, this multiplexed nicking strategy can improve specificity by up to 1,500× relative to the wild-type Cas9 (Ran et al., 2013).

Because Cas9 nuclease or multiplex nicking activity both stimulate NHEJ, a population of cells cotargeted with a homology donor would eventually possess a mix of indel mutants and donor integrants. Single DNA nicks, however, are also able to mediate donor recombination, albeit at a lower level than with DSBs (Hsu et al., 2013). Cas9 nickases with single sgRNAs can thus be used to mediate HR rather than NHEJ. Furthermore, off-target integration is highly unlikely due to long homology arms flanking the donor cassette.

In addition to the double-nicking strategy, sgRNAs truncated by 2 or 3 nt have been reported to significantly increase targeting specificity of SpCas9, potentially due to greater mismatch sensitivity (Fu et al., 2014). These truncated sgRNAs can be combined




Figure 6. Applications of Cas9 as a Genome Engineering Platform

(A) The Cas9 nuclease cleaves DNA via its RuvC and HNH nuclease domains, each of which nicks a DNA strand to generate blunt-end DSBs. Either catalytic domain can be inactivated to generate nickase mutants that cause single-strand DNA breaks.

(B) Two Cas9 nickase complexes with appropriately spaced target sites can mimic targeted DSBs via cooperative nicks, doubling the length of target recognition without sacrificing cleavage efficiency.

(C) Expression plasmids encoding the Cas9 gene and a short sgRNA cassette driven by the U6 RNA polymerase III promoter can be directly transfected into cell lines of interest.

(D) Purified Cas9 protein and in vitro transcribed sgRNA can be microinjected into fertilized zygotes for rapid generation of transgenic animal models.

(E) For somatic genetic modification, high-titer viral vectors encoding CRISPR reagents can be transduced into tissues or cells of interest.

(F) Genome-scale functional screening can be facilitated by mass synthesis and delivery of guide RNA libraries.

(G) Catalytically dead Cas9 (dCas9) can be converted into a general DNA-binding domain and fused to functional effectors such as transcriptional activators or epigenetic enzymes. The modularity of targeting and flexible choice of functional domains enable rapid expansion of the Cas9 toolbox.

(H) Cas9 coupled to fluorescent reporters facilitates live imaging of DNA loci for illuminating the dynamics of genome architecture.

(I) Reconstituting split fragments of Cas9 via chemical or optical induction of heterodimer domains, such as the cib1/cry2 system from *Arabidopsis*, confers temporal control of dynamic cellular processes.

with multiplex nicking to further reduce off-target mutagenesis (Fu et al., 2014). Future structure-function analyses and Cas9 and protein engineering via rational design or directed evolution may lead to further improvements in Cas9 specificity.

Applications of Cas9 in Research, Medicine, and Biotechnology

Cas9 can be used to facilitate a wide variety of targeted genome engineering applications. The wild-type Cas9 nuclease has enabled efficient and targeted genome modification in many species that have been intractable using traditional genetic manipulation techniques. The ease of retargeting Cas9 by simply designing a short RNA sequence also enables large-scale unbiased genome perturbation experiments to probe gene function or elucidate causal genetic variants. In addition to facilitating covalent genome modifications, the wild-type Cas9 nuclease can also be converted into a generic RNA-guided homing device (dCas9) by inactivating the catalytic domains. The use of effector fusions can greatly expand the repertoire of genome engineering modalities achievable using Cas9. For example, a variety of proteins or RNAs can be tethered to Cas9 or sgRNA to alter transcription states of specific genomic loci, monitor chromatin

states, or even rearrange the three-dimensional organization of the genome.

Rapid Generation of Cellular and Animal Models

Cas9-mediated genome editing has enabled accelerated generation of transgenic models and expands biological research beyond traditional, genetically tractable animal model organisms (Sander and Joung, 2014). By recapitulating genetic mutations found in patient populations, CRISPR-based editing could be used to rapidly model the causal roles of specific genetic variations instead of relying on disease models that only phenocopy a particular disorder. This could be applied to develop novel transgenic animal models (Wang et al., 2013; Niu et al., 2014), to engineer isogenic ES and iPS cell disease models with specific mutations introduced or corrected, respectively, or in vivo and ex vivo gene correction (Schwank et al., 2013; Wu et al., 2013).

For generation of cellular models, Cas9 can be easily introduced into the target cells using transient transfection of plasmids carrying Cas9 and the appropriately designed sgRNA (Figure 6C). Additionally, the multiplexing capabilities of Cas9 offer a promising approach for studying common human diseases—such as diabetes, heart disease, schizophrenia, and autism—that are typically polygenic. Large-scale genome-wide

association studies (GWAS), for example, have identified haplotypes that show strong association with disease risk. However, it is often difficult to determine which of several genetic variants in tight linkage disequilibrium with the haplotype or which of several genes in the region are responsible for the phenotype. Using Cas9, one could study the effect of each individual variant or test the effect of manipulating each individual gene on an isogenic background by editing stem cells and differentiating them into cell types of interest.

For generation of transgenic animal models, Cas9 protein and transcribed sgRNA can be directly injected into fertilized zygotes to achieve heritable gene modification at one or multiple alleles in models such as rodents and monkeys (Wang et al., 2013; Li et al., 2013; Yang et al., 2013; Niu et al., 2014) (Figure 6D). By bypassing the typical ES cell targeting stage in generating transgenic lines, the generation time for mutant mice and rats can be reduced from more than a year to only several weeks. Such advances will facilitate cost-effective and large-scale *in vivo* mutagenesis studies in rodent models and can be combined with highly specific editing (Fu et al., 2014; Ran et al., 2013) to avoid confounding off-target mutagenesis. Successful multiplex targeting in cynomolgus monkey models was also recently reported (Niu et al., 2014), suggesting the potential for establishing more accurate modeling of complex human diseases such as neuropsychiatric disorders using primate models. Additionally, Cas9 could be harnessed for direct modification of somatic tissue, obviating the need for embryonic manipulation (Figure 6E) as well as enabling therapeutic use for gene therapy.

One outstanding challenge with transgenic animal models generated via zygotic injection of CRISPR reagents is genetic mosaicism, partly due to a slow rate of nuclease-induced mutagenesis. Studies to date have typically relied on the injection of Cas9 mRNA into zygotes (fertilized embryos at the single-cell stage). However, because transcription and translation activity is suppressed in the mouse zygote, Cas9 mRNA translation into active enzymatic form is likely delayed until after the first cell division (Oh et al., 2000). Because NHEJ-mediated repair is thought to introduce indels of random length, this translation delay likely plays a major role in contributing to genetic mosaicism in CRISPR-modified mice. To overcome this limitation, Cas9 protein and sgRNA could be directly injected into single-cell fertilized embryos. The high rate of nonmutagenic repair by the NHEJ process may additionally contribute to undesired mosaicism because introducing indels that mutate the Cas9 recognition site would then have to compete with zygotic division rates. To increase the mutagenic activity of NHEJ, a pair of sgRNAs flanking a small fragment of the target gene may be used to increase the probability of gene disruption.

Functional Genomic Screens

The efficiency of genome editing with Cas9 makes it possible to alter many targets in parallel, thereby enabling unbiased genome-wide functional screens to identify genes that play an important role in a phenotype of interest. Lentiviral delivery of sgRNAs directed against all genes (either together with Cas9 or to cells already expressing Cas9) can be used to perturb thousands of genomic elements in parallel. Recent papers have demonstrated the ability to perform robust negative and positive

selection screens in human cells (Wang et al., 2014; Shalem et al., 2014) by introducing loss-of-function mutations into early, constitutive coding exons of a different gene in each cell (Figure 6F). Genome-wide loss-of-function screens have previously used RNAi, but this approach leads to only partial knockdown, has extensive off-target effects, and is limited to transcribed (and usually protein-coding) genes. By contrast, Cas9-mediated pooled sgRNA screens have been shown to provide increased screening sensitivity as well as consistency and can be designed to target nearly any DNA sequence (Shalem et al., 2014).

Future applications of single sgRNA libraries may also enable the perturbation of noncoding genetic elements, while multiplex sgRNA delivery may be used to dissect the function of large genomic regions through tiled microdeletions. For example, systematic targeting of gene regulatory regions could facilitate the discovery of distant enhancers, general promoter architectures, and any additional regulatory elements that have an effect on protein levels. An additional application could be to dissect large, uncharacterized genomic regions that are implicated in sequencing studies or GWAS.

Tethering dCas9 to different effector domains may also facilitate genomic screens beyond loss-of-function phenotypes. dCas9 fused to epigenetic modifiers, for instance, could be used to study the effects of methylation or certain chromatin states on cellular differentiation or disease pathologies, whereas transcriptional activators allow screening for gain-of-function phenotypes. Using truncated sgRNAs or building redundancy with several sgRNAs targeting each locus would be important design principles for filtering out false positive signals and improving the interpretability of screening data.

Transcriptional Modulation

dCas9 binding alone to DNA elements may repress transcription by sterically hindering RNA polymerase machinery (Qi et al., 2013), likely by stalling transcriptional elongation. This CRISPR-based interference, or CRISPRi, works efficiently in prokaryotic genomes but is less effective in eukaryotic cells (Gilbert et al., 2013). The repressive function of CRISPRi can be enhanced by tethering dCas9 to transcriptional repressor domains such as KRAB or SID effectors, which promote epigenetic silencing (Gilbert et al., 2013; Konermann et al., 2013). However, dCas9-mediated transcriptional repression needs to be further improved—in the current generation of dCas9-based eukaryotic transcription repressors, even the addition of helper functional domains results in only partial transcriptional knockdown (Gilbert et al., 2013; Konermann et al., 2013).

Cas9 can also be converted into a synthetic transcriptional activator by fusing it to VP16/VP64 or p65 activation domains (Figure 6G). In general, targeting Cas9 activators with a single sgRNA to a particular endogenous gene promoter leads to only modest transcriptional upregulation (Konermann et al., 2013; Maeder et al., 2013b; Perez-Pinera et al., 2013; Mali et al., 2013b). By tiling a promoter with multiple sgRNAs, several groups have reported strong synergistic effects with nonlinear increases in activation (Perez-Pinera et al., 2013; Maeder et al., 2013b; Mali et al., 2013b). Although the requirement for multiple sgRNAs to achieve efficient transcription activation is potentially advantageous for increased specificity, screening applications

employing libraries of sgRNAs will require highly efficient and specific transcriptional control using individual guide RNAs.

Epigenetic Control

Complex genome functions are defined by the highly dynamic landscape of epigenetic states. Epigenetic modifications that tune histones are thus crucial for transcriptional regulation and play important roles in a variety of biological functions. These marks, such as DNA methylation or histone acetylation, are established and maintained in mammalian cells by a variety of enzymes that are recruited to specific genomic loci either directly or indirectly through scaffolding proteins.

Previously, zinc finger proteins and TAL effectors have been used in a small number of proof-of-concept studies to achieve locus-specific targeting of epigenetic modifying enzymes (Beerli et al., 2000a; Konermann et al., 2013; Maeder et al., 2013a; Mendenhall et al., 2013). Cas9 epigenetic effectors (epiCas9s) that can artificially install or remove specific epigenetic marks at specific loci would serve as a more flexible platform to probe the causal effects of epigenetic modifications in shaping the regulatory networks of the genome (Figure 6G). Of course, the potential for off-target activity or crosstalk between effector domains and endogenous epigenetic complexes would need to be carefully characterized. One solution could be to harness prokaryotic epigenetic enzymes to develop orthogonal epigenetic regulatory systems that minimize crosstalk with endogenous proteins.

Live Imaging of the Cellular Genome

The spatial organization of functional and structural elements within the cell contribute to the functional output of genomes, which can be amplified or suppressed dynamically. However, the way that genomes are modified and how their structural organization in vivo modulates functional output remain unclear. Genomic loci located megabases apart or on entirely different chromosomes could be brought into close proximity given appropriate chromosomal organization, thus mediating long-range *trans* interactions.

Studying the interactions of specific genes given changing chromatin states would require a robust method to visualize DNA in living cells. Traditional techniques for labeling DNA, such as fluorescence in situ hybridization (FISH), require sample fixation and are thus unable to capture live processes. Fluorescently tagged Cas9 labeling of specific DNA loci was recently developed as a powerful live-cell-imaging alternative to DNA-FISH (Chen et al., 2013) (Figure 6H). Advances in orthogonal Cas9 proteins or modified sgRNAs will build out multi-color and multi-locus capabilities to enhance the utility of CRISPR-based imaging for studying complex chromosomal architecture and nuclear organization.

Inducible Regulation of Cas9 Activity

By exploiting the bilobed structure of Cas9, it may be possible to split the protein into two units and control their reassembly via small-molecule or light-inducible heterodimeric domains (Figure 6I). Small-molecule induction would facilitate systemic control of Cas9 in patients or animal models, whereas optical regulation enables more spatially precise perturbation. For example, the light-inducible dimerization domains CIB1 and CRY2 or chemically inducible analogs ABI and PYL, which have been successfully used to construct inducible TALEs (Konermann et al., 2013), may be adapted to engineer inducible Cas9 systems.

Future Development of Cas9-Based Genome Engineering Technologies

Unbiased Analysis of Cas9 Binding and Cleavage

Despite the rapid adoption of Cas9 as a platform technology for genetic and epigenetic perturbation and significant progress in understanding and improving Cas9 specificity, its on- and off-target DNA binding and cleavage profiles still need to be thoroughly evaluated. Studies to date characterizing Cas9 off-target activity have relied on *in silico* computational prediction or *in vitro* selection. As a result, they have been unable to account for the likelihood of Cas9 activity that is unpredictable by sequence homology to the sgRNA guide sequence.

Because the off-target activity of dCas9 binding for effector domain localization may be much more extensive than Cas9-mediated genome editing, unbiased profiling methods are needed to refine our understanding of “true positive” Cas9 off-target activity that actually leads to undesired functional outcomes. Cas9-based chromatin immunoprecipitation sequencing (ChIP-seq) analysis at multiple target sites could be a high-throughput solution for understanding binding degeneracy (Wu et al., 2014), whereas techniques for detecting and labeling double-strand breaks (Crosetto et al., 2013) will help to achieve a comprehensive map of Cas9-induced off-target indels.

These data together will help to generate predictive models for minimizing off-target activity in gene therapeutics or other applications requiring high levels of precision. Understanding Cas9 binding and cleavage in the context of chromatin accessibility and epigenetic states will also inform better computational evaluation of guide RNA specificity. For example, particular sgRNAs could be evaluated based on the genomic nature of its off-target sites, which would vary by guide sequence. Degenerate targeting of transcriptionally silent genes for a cell type or tissue of interest would likely be preferred to off-target sites in the coding region of essential housekeeping genes.

Although it is still unclear how Cas9 is affected by chromatin accessibility and heterochromatin versus euchromatin, dCas9 transcriptional activators can upregulate transcription at sites lacking DNase I hypersensitivity sites, indicating successful binding to inaccessible chromatin (Perez-Pinera et al., 2013) (Figure 6G). CpG methylation does not appear to affect DNA cleavage *in vitro*, and Cas9 could introduce indels at a highly methylated promoter *in vivo* (Hsu et al., 2013). It will be important to evaluate Cas9 binding and cleavage of genomic loci in relevant primary cells with different chromatin states, ideally in post-mitotic cells in which genomic architecture is stably defined.

Overall, these efforts aimed at improving our understanding of Cas9 binding and cleavage specificity will complement existing methods (Mali et al., 2013b; Ran et al., 2013; Fu et al., 2014) as well as future protein engineering and metagenomic mining efforts to improve Cas9 specificity and the selection of guide RNA target sites.

Development of Versatile Delivery and Expression Systems for Applications of Cas9

Viral vectors such as adeno-associated virus (AAV) or lentivirus are commonly used for delivering genes of interest *in vivo* or into cell types resistant to common transfection methods, such as immune cells. AAV vectors have been commonly used for

attractive candidates for efficient gene delivery in vivo because of their low immunogenic potential, reduced oncogenic risk from host-genome integration, and well-characterized serotype specificity (Figure 6E). However, the most commonly used Cas9 nuclease-encoding gene from *Streptococcus pyogenes* is >4 kb in length, which is difficult to transduce using AAV due to its 4.7 kb packaging capacity. Non-viral approaches for introducing CRISPR reagents in vivo present a fertile ground for developing novel delivery strategies, from liposomes and aptamers to cell-penetrating peptides and the molecular Trojan horse (Niewoehner et al., 2014).

However, viral approaches are still highly desirable due to their low immunogenicity and wide array of characterized tropisms. The size constraints of viral vectors can be sidestepped by using significantly smaller Cas9 orthologs derived from metagenomic discovery, several of which have already been characterized and validated in human cells (Cong et al., 2013; Hou et al., 2013; Esvelt et al., 2013). Interestingly, short Cas9 variants reported to date recognize much longer PAM sequences than SpCas9 (5'-NNAGAAW from *Streptococcus thermophilus* CRISPR1 or 5'-NNNGATT from *Neisseria meningitidis*) (Zhang et al., 2013; Garneau et al., 2010), whereas some longer orthologs have more relaxed PAMs (5'-NG from *Francisella novicida*) (Fonfara et al., 2014). Although the effect of PAM restriction on DNA targeting specificity remains to be investigated, the more limited overall targeting range of short Cas9 variants may be partially compensated for by decreasing the number of potential off-target substrates genome-wide.

Moving beyond Endogenous Cellular Repair

The current generation of genome editing technologies depends on the endogenous DNA repair machinery to introduce loss-of-function mutations or precise modifications (Figure 2A). Although Cas9 can be used to generate indel mutations via NHEJ with high efficiency, the absolute rate of HDR remains relatively low. Although it is sufficient for the generation of cell lines, especially when paired with drug selection or FACS enrichment, poor rates of recombination greatly limit the practical utility of Cas9-mediated targeted gene insertion in fertilized zygotes or somatic tissue. Homologous recombination proteins are also mainly expressed in the G2 phase of the cell cycle, making HDR-based gene editing difficult in postmitotic cells such as neurons or cardiac myocytes. As a result, methods for stimulating HDR-based repair or alternative strategies for efficient gene insertion are urgently needed. For instance, the highly efficient DNA damage repair system in *Deinococcus radiodurans* (Zahradka et al., 2006) may be exploited to enable efficient genome editing in mitotic as well as postmitotic cells.

Furthermore, the majority of CRISPR-based technology development has focused on the signature Cas9 nuclease from type II CRISPR systems. However, there remains a wide diversity of CRISPR types and functions. Cas RAMP module (Cmr) proteins identified in *Pyrococcus furiosus* and *Sulfolobus solfataricus* (Hale et al., 2012) constitute an RNA-targeting CRISPR immune system, forming a complex guided by small CRISPR RNAs that target and cleave complementary RNA instead of DNA. Cmr protein homologs can be found throughout bacteria and archaea, typically relying on a 5' site tag sequence on the target-matching crRNA for Cmr-directed cleavage.

Unlike RNAi, which is targeted largely by a 6 nt seed region and to a lesser extent 13 other bases, Cmr crRNAs contain 30–40 nt of target complementarity. Cmr-CRISPR technologies for RNA targeting are thus a promising target for orthogonal engineering and minimal off-target modification. Although the modularity of Cmr systems for RNA-targeting in mammalian cells remains to be investigated, Cmr complexes native to *P. furiosus* have already been engineered to target novel RNA substrates (Hale et al., 2009, 2012).

Cas9 as a Therapeutic Molecule for Treating Genetic Disorders

Although Cas9 has already been widely used as a research tool, a particularly exciting future direction is the development of Cas9 as a therapeutic technology for treating genetic disorders. For a monogenic recessive disorder due to loss-of-function mutations (such as cystic fibrosis, sickle-cell anemia, or Duchenne muscular dystrophy), Cas9 may be used to correct the causative mutation. This has many advantages over traditional methods of gene augmentation that deliver functional genetic copies via viral vector-mediated overexpression—particularly that the newly functional gene is expressed in its natural context. For dominant-negative disorders in which the affected gene is haplosufficient (such as transthyretin-related hereditary amyloidosis or dominant forms of retinitis pigmentosa), it may also be possible to use NHEJ to inactivate the mutated allele to achieve therapeutic benefit. For allele-specific targeting, one could design guide RNAs capable of distinguishing between single-nucleotide polymorphism (SNP) variations in the target gene, such as when the SNP falls within the PAM sequence.

Some monogenic diseases also result from duplication of genomic sequences. For these diseases, the multiplexing capability of Cas9 may be exploited for deletion of the duplicated elements. For example, trinucleotide repeat disorders could be treated using two simultaneous DSBs to excise the repeat region. The success of this strategy will likely be higher for diseases such as Friedreich's ataxia, in which duplications occur in noncoding regions of the target gene, because NHEJ-mediated repair may lead to imperfect or frameshifted repair junctions.

In addition to repairing mutations underlying inherited disorders, Cas9-mediated genome editing might be used to introduce protective mutations in somatic tissues to combat nongenetic or complex diseases. For example, NHEJ-mediated inactivation of the CCR5 receptor in lymphocytes (Lombardo et al., 2007) may be a viable strategy for circumventing HIV infection, whereas deletion of PCSK9 (Cohen et al., 2005) or angiopoietin (Musunuru et al., 2010) may provide therapeutic effects against statin-resistant hypercholesterolemia or hyperlipidemia. Although these targets may be also addressed using siRNA-mediated protein knockdown, a unique advantage of NHEJ-mediated gene inactivation is the ability to achieve permanent therapeutic benefit without the need for continuing treatment. As with all gene therapies, it will of course be important to establish that each proposed therapeutic use has a favorable benefit-risk ratio.

Cas9 could be used beyond the direct genome modification of somatic tissue, such as for engineering therapeutic cells. Chimeric antigen receptor (CAR) T cells can be modified

ex vivo and reinfused into a patient to specifically target certain cancers (Cousin-Frankel, 2013). The ease of design and testing of Cas9 may also facilitate the treatment of highly rare genetic variants through personalized medicine. Supporting these tremendous possibilities are a number of animal model studies as well as clinical trials using programmable nucleases that already provide important insights into the future development of Cas9-based therapeutics.

Recently, hydrodynamic delivery of plasmid DNA encoding Cas9 and sgRNA along with a repair template into the liver of an adult mouse model of tyrosinemia was shown to be able to correct the mutant *Fah* gene and rescue expression of the wild-type *Fah* protein in ~1 out of 250 cells (Yin et al., 2014). In addition, clinical trials successfully used ZF nucleases to combat HIV infection by ex vivo knockout of the CCR5 receptor. In all patients, HIV DNA levels decreased, and in one out of four patients, HIV RNA became undetectable (Tebas et al., 2014). Both of these results demonstrate the promise of programmable nucleases as a new therapeutic platform.

However, numerous challenges still lie ahead. Most importantly, successful clinical translation will depend on appropriate and efficacious delivery systems to target specific disease tissues. To achieve high levels of therapeutic efficacy and simultaneously address a broad spectrum of genetic disorders, homologous recombination efficiency will need to be significantly improved. Although permanent genome modification has advantages over monoclonal antibody or siRNA treatments, which require repeated administration of the therapeutic molecule, the long-term implications remain unclear. As researchers further develop and test Cas9 toward clinical translation, it will be paramount to thoroughly characterize the safety as well as physiological effects of Cas9 using a variety of preclinical models.

Conclusions

The story of how a mysterious prokaryotic viral defense system became one of the most powerful and versatile platforms for engineering biology highlights the importance of basic science research. Just as recombinant DNA technology benefited from basic investigation of the restriction enzymes that are central to warfare between phage and bacteria, the latest generation of Cas9-based genome engineering tools are also based on components from the microbial antiphage defense system. It is highly likely that the future solutions for efficient and precise gene modification will be found in as of yet unexplored corners of the rich biological diversity of nature.

SUPPLEMENTAL INFORMATION

Supplemental Information includes one movie and can be found with this article at <http://dx.doi.org/10.1016/j.cell.2014.05.010>.

ACKNOWLEDGMENTS

We gratefully acknowledge Sigrid Knemeyer for help with illustration; Ian Slaymaker for structural guidance; Chengwei Luo for expertise in phylogenetic analysis; Emmanuelle Charpentier, Philippe Horvath, Charles Jennings, Ellen Law, Luciano Marraffini, Francisco Mojica, Hiroshi Nishimasu, Virginijus Siksnys, and Alexandro Trevino for discussion and comments; and the

CRISPR community for this beautiful story. P.D.H. is a James Mills Pierce Fellow. This work is supported by the NIMH through a NIH Director's Pioneer Award (DP1-MH100706), the NINDS through a NIH Transformative R01 grant (R01-NS 07312401), NSF, the Keck, McKnight, Damon Runyon, Searle Scholars, Klingenstein, Vallee, Merkin, and Simons Foundations, and Bob Metcalfe. CRISPR reagents are available to the academic community through Addgene, and associated protocols, support forum, and computational tools are available via the Zhang lab website (<http://www.genome-engineering.org>).

REFERENCES

- Barrangou, R., and van der Oost, J. (2013). CRISPR-Cas Systems: RNA-Mediated Adaptive Immunity in Bacteria and Archaea (Heidelberg, Germany: Springer).
- Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D.A., and Horvath, P. (2007). CRISPR provides acquired resistance against viruses in prokaryotes. *Science* 315, 1709–1712.
- Beerli, R.R., Dreier, B., and Barbas, C.F., 3rd. (2000a). Positive and negative regulation of endogenous genes by designed transcription factors. *Proc. Natl. Acad. Sci. USA* 97, 1495–1500.
- Beerli, R.R., Schopfer, U., Dreier, B., and Barbas, C.F., 3rd. (2000b). Chemically regulated zinc finger transcription factors. *J. Biol. Chem.* 275, 32617–32627.
- Bibikova, M., Carroll, D., Segal, D.J., Trautman, J.K., Smith, J., Kim, Y.G., and Chandrasegaran, S. (2001). Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. *Mol. Cell. Biol.* 21, 289–297.
- Bibikova, M., Golic, M., Golic, K.G., and Carroll, D. (2002). Targeted chromosomal cleavage and mutagenesis in *Drosophila* using zinc-finger nucleases. *Genetics* 161, 1169–1175.
- Bibikova, M., Beumer, K., Trautman, J.K., and Carroll, D. (2003). Enhancing gene targeting with designed zinc finger nucleases. *Science* 300, 764.
- Boch, J., Scholze, H., Schornack, S., Landgraf, A., Hahn, S., Kay, S., Lahaye, T., Nickstadt, A., and Bonas, U. (2009). Breaking the code of DNA binding specificity of TAL-type III effectors. *Science* 326, 1509–1512.
- Bolotin, A., Quinquis, B., Sorokin, A., and Ehrlich, S.D. (2005). Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. *Microbiology* 151, 2551–2561.
- Brouns, S.J., Jore, M.M., Lundgren, M., Westra, E.R., Slijkhuys, R.J., Snijders, A.P., Dickman, M.J., Makarova, K.S., Koonin, E.V., and van der Oost, J. (2008). Small CRISPR RNAs guide antiviral defense in prokaryotes. *Science* 321, 960–964.
- Capecci, M.R. (1989). Altering the genome by homologous recombination. *Science* 244, 1288–1292.
- Chen, B., Gilbert, L.A., Cimini, B.A., Schnitzbauer, J., Zhang, W., Li, G.W., Park, J., Blackburn, E.H., Weissman, J.S., Qi, L.S., and Huang, B. (2013). Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. *Cell* 155, 1479–1491.
- Cho, S.W., Kim, S., Kim, J.M., and Kim, J.S. (2013). Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. *Nat. Biotechnol.* 31, 230–232.
- Choulika, A., Perrin, A., Dujon, B., and Nicolas, J.F. (1995). Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* 15, 1968–1973.
- Christian, M., Cermak, T., Doyle, E.L., Schmidt, C., Zhang, F., Hummel, A., Bogdanove, A.J., and Voytas, D.F. (2010). Targeting DNA double-strand breaks with TAL effector nucleases. *Genetics* 186, 757–761.
- Chylinski, K., Le Rhun, A., and Charpentier, E. (2013). The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems. *RNA Biol.* 10, 726–737.
- Chylinski, K., Makarova, K.S., Charpentier, E., and Koonin, E.V. (2014). Classification and evolution of type II CRISPR-Cas systems. *Nucleic Acids Res.* Published online Apr 11, 2014. <http://dx.doi.org/10.1093/nar/gku241>.
- Cohen, J., Pertsemlidis, A., Kotowski, I.K., Graham, R., Garcia, C.K., and Hobbs, H.H. (2005). Low LDL cholesterol in individuals of African descent

- resulting from frequent nonsense mutations in PCSK9. *Nat. Genet.* 37, 161–165.
- Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., and Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. *Science* 339, 819–823.
- Couzin-Frankel, J. (2013). Breakthrough of the year 2013. Cancer immunotherapy. *Science* 342, 1432–1433.
- Crosetto, N., Mitra, A., Silva, M.J., Bienko, M., Dojer, N., Wang, Q., Karaca, E., Chiarle, R., Skrzypczak, M., Ginalski, K., et al. (2013). Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing. *Nat. Methods* 10, 361–365.
- Deltcheva, E., Chylinski, K., Sharma, C.M., Gonzales, K., Chao, Y., Pirzada, Z.A., Eckert, M.R., Vogel, J., and Charpentier, E. (2011). CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. *Nature* 471, 602–607.
- Deveau, H., Barrangou, R., Garneau, J.E., Labonté, J., Fremaux, C., Boyaval, P., Romero, D.A., Horvath, P., and Moineau, S. (2008). Phage response to CRISPR-encoded resistance in *Streptococcus thermophilus*. *J. Bacteriol.* 190, 1390–1400.
- Dianov, G.L., and Hübscher, U. (2013). Mammalian base excision repair: the forgotten archangel. *Nucleic Acids Res.* 41, 3483–3490.
- Esvelt, K.M., Mali, P., Braff, J.L., Moosburner, M., Yaung, S.J., and Church, G.M. (2013). Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. *Nat. Methods* 10, 1116–1121.
- Fonfara, I., Le Rhun, A., Chylinski, K., Makarova, K.S., Lécrivain, A.L., Bzdrenga, J., Koonin, E.V., and Charpentier, E. (2014). Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems. *Nucleic Acids Res.* 42, 2577–2590.
- Fu, Y., Foden, J.A., Khayter, C., Maeder, M.L., Reyon, D., Joung, J.K., and Sander, J.D. (2013). High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. *Nat. Biotechnol.* 31, 822–826.
- Fu, Y., Sander, J.D., Reyon, D., Cascio, V.M., and Joung, J.K. (2014). Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. *Nat. Biotechnol.* 32, 279–284.
- Gabriel, R., Lombardo, A., Arens, A., Miller, J.C., Genovese, P., Kaeppl, C., Nowrouzi, A., Bartholomae, C.C., Wang, J., Friedman, G., et al. (2011). An unbiased genome-wide analysis of zinc-finger nuclease specificity. *Nat. Biotechnol.* 29, 816–823.
- Garneau, J.E., Dupuis, M.E., Villion, M., Romero, D.A., Barrangou, R., Boyaval, P., Fremaux, C., Horvath, P., Magadán, A.H., and Moineau, S. (2010). The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. *Nature* 468, 67–71.
- Gasiunas, G., Barrangou, R., Horvath, P., and Siksnys, V. (2012). Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. *Proc. Natl. Acad. Sci. USA* 109, E2579–E2586.
- Gilbert, L.A., Larson, M.H., Morsut, L., Liu, Z., Brar, G.A., Torres, S.E., Stern-Ginossar, N., Brandman, O., Whitehead, E.H., Doudna, J.A., et al. (2013). CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. *Cell* 154, 442–451.
- Gonzalez, B., Schwimmer, L.J., Fuller, R.P., Ye, Y., Asawapornmongkol, L., and Barbas, C.F. (2010). Modular system for the construction of zinc-finger libraries and proteins. *Nat. Protoc.* 5, 791–810.
- Haft, D.H., Selengut, J., Mongodin, E.F., and Nelson, K.E. (2005). A guild of 45 CRISPR-associated (Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic genomes. *PLoS Comput. Biol.* 1, e60.
- Hale, C.R., Zhao, P., Olson, S., Duff, M.O., Graveley, B.R., Wells, L., Terns, R.M., and Terns, M.P. (2009). RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex. *Cell* 139, 945–956.
- Hale, C.R., Majumdar, S., Elmore, J., Pfister, N., Compton, M., Olson, S., Resch, A.M., Glover, C.V., 3rd, Graveley, B.R., Terns, R.M., and Terns, M.P. (2012). Essential features and rational design of CRISPR RNAs that function with the Cas RAMP module complex to cleave RNAs. *Mol. Cell* 45, 292–302.
- Horvath, P., Romero, D.A., Coûté-Monvoisin, A.C., Richards, M., Deveau, H., Moineau, S., Boyaval, P., Fremaux, C., and Barrangou, R. (2008). Diversity, activity, and evolution of CRISPR loci in *Streptococcus thermophilus*. *J. Bacteriol.* 190, 1401–1412.
- Horvath, P., Coûté-Monvoisin, A.C., Romero, D.A., Boyaval, P., Fremaux, C., and Barrangou, R. (2009). Comparative analysis of CRISPR loci in lactic acid bacteria genomes. *Int. J. Food Microbiol.* 131, 62–70.
- Hou, Z., Zhang, Y., Propson, N.E., Howden, S.E., Chu, L.F., Sontheimer, E.J., and Thomson, J.A. (2013). Efficient genome engineering in human pluripotent stem cells using Cas9 from *Neisseria meningitidis*. *Proc. Natl. Acad. Sci. USA* 110, 15644–15649.
- Hsu, P.D., Scott, D.A., Weinstein, J.A., Ran, F.A., Konermann, S., Agarwala, V., Li, Y., Fine, E.J., Wu, X., Shalem, O., et al. (2013). DNA targeting specificity of RNA-guided Cas9 nucleases. *Nat. Biotechnol.* 31, 827–832.
- Ishino, Y., Shinagawa, H., Makino, K., Amemura, M., and Nakata, A. (1987). Nucleotide sequence of the *iap* gene, responsible for alkaline phosphatase isozyme conversion in *Escherichia coli*, and identification of the gene product. *J. Bacteriol.* 169, 5429–5433.
- Jansen, R., Embden, J.D., Gaastra, W., and Schouls, L.M. (2002). Identification of genes that are associated with DNA repeats in prokaryotes. *Mol. Microbiol.* 43, 1565–1575.
- Jiang, W., Bikard, D., Cox, D., Zhang, F., and Marraffini, L.A. (2013). RNA-guided editing of bacterial genomes using CRISPR-Cas systems. *Nat. Biotechnol.* 31, 233–239.
- Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., and Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* 337, 816–821.
- Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., and Doudna, J. (2013). RNA-programmed genome editing in human cells. *eLife* 2, e00471.
- Jinek, M., Jiang, F., Taylor, D.W., Sternberg, S.H., Kaya, E., Ma, E., Anders, C., Hauer, M., Zhou, K., Lin, S., et al. (2014). Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. *Science* 343, 1247997.
- Juillerat, A., Dubois, G., Valton, J., Thomas, S., Stella, S., Maréchal, A., Langevin, S., Benomari, N., Bertonati, C., Silva, G.H., et al. (2014). Comprehensive analysis of the specificity of transcription activator-like effector nucleases. *Nucleic Acids Res.* 42, 5390–5402.
- Konermann, S., Brigham, M.D., Trevino, A.E., Hsu, P.D., Heidenreich, M., Cong, L., Platt, R.J., Scott, D.A., Church, G.M., and Zhang, F. (2013). Optical control of mammalian endogenous transcription and epigenetic states. *Nature* 500, 472–476.
- Li, W., Teng, F., Li, T., and Zhou, Q. (2013). Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. *Nat. Biotechnol.* 31, 684–686.
- Lombardo, A., Genovese, P., Beausejour, C.M., Colleoni, S., Lee, Y.L., Kim, K.A., Ando, D., Urnov, F.D., Galli, C., Gregory, P.D., et al. (2007). Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. *Nat. Biotechnol.* 25, 1298–1306.
- Maeder, M.L., Thibodeau-Beganny, S., Osiak, A., Wright, D.A., Anthony, R.M., Eichinger, M., Jiang, T., Foley, J.E., Winfrey, R.J., Townsend, J.A., et al. (2008). Rapid “open-source” engineering of customized zinc-finger nucleases for highly efficient gene modification. *Mol. Cell* 31, 294–301.
- Maeder, M.L., Angstman, J.F., Richardson, M.E., Linder, S.J., Cascio, V.M., Tsai, S.Q., Ho, Q.H., Sander, J.D., Reyon, D., Bernstein, B.E., et al. (2013a). Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. *Nat. Biotechnol.* 31, 1137–1142.
- Maeder, M.L., Linder, S.J., Cascio, V.M., Fu, Y., Ho, Q.H., and Joung, J.K. (2013b). CRISPR RNA-guided activation of endogenous human genes. *Nat. Methods* 10, 977–979.
- Makarova, K.S., Grishin, N.V., Shabalina, S.A., Wolf, Y.I., and Koonin, E.V. (2006). A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action. *Biol. Direct* 1, 7.

- Makarova, K.S., Aravind, L., Wolf, Y.I., and Koonin, E.V. (2011a). Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems. *Biol. Direct* 6, 38.
- Makarova, K.S., Haft, D.H., Barrangou, R., Brouns, S.J., Charpentier, E., Horvath, P., Moineau, S., Mojica, F.J., Wolf, Y.I., Yakunin, A.F., et al. (2011b). Evolution and classification of the CRISPR-Cas systems. *Nat. Rev. Microbiol.* 9, 467–477.
- Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, J.E., Norville, J.E., and Church, G.M. (2013a). RNA-guided human genome engineering via Cas9. *Science* 339, 823–826.
- Mali, P., Aach, J., Stranges, P.B., Esvelt, K.M., Moosburner, M., Kosuri, S., Yang, L., and Church, G.M. (2013b). CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. *Nat. Biotechnol.* 31, 833–838.
- Marraffini, L.A., and Sontheimer, E.J. (2008). CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. *Science* 322, 1843–1845.
- Marraffini, L.A., and Sontheimer, E.J. (2010). Self versus non-self discrimination during CRISPR RNA-directed immunity. *Nature* 463, 568–571.
- Mendenhall, E.M., Williamson, K.E., Reyon, D., Zou, J.Y., Ram, O., Joung, J.K., and Bernstein, B.E. (2013). Locus-specific editing of histone modifications at endogenous enhancers. *Nat. Biotechnol.* 31, 1133–1136.
- Miller, J.C., Holmes, M.C., Wang, J., Guschin, D.Y., Lee, Y.L., Rupniewski, I., Beausejour, C.M., Waite, A.J., Wang, N.S., Kim, K.A., et al. (2007). An improved zinc-finger nuclease architecture for highly specific genome editing. *Nat. Biotechnol.* 25, 778–785.
- Miller, J.C., Tan, S., Qiao, G., Barlow, K.A., Wang, J., Xia, D.F., Meng, X., Paschon, D.E., Leung, E., Hinkley, S.J., et al. (2011). A TALE nuclease architecture for efficient genome editing. *Nat. Biotechnol.* 29, 143–148.
- Mojica, F.J., Díez-Villaseñor, C., Soria, E., and Juez, G. (2000). Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria. *Mol. Microbiol.* 36, 244–246.
- Mojica, F.J., Díez-Villaseñor, C., García-Martínez, J., and Soria, E. (2005). Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. *J. Mol. Evol.* 60, 174–182.
- Moscou, M.J., and Bogdanove, A.J. (2009). A simple cipher governs DNA recognition by TAL effectors. *Science* 326, 1501.
- Musunuru, K., Pirruccello, J.P., Do, R., Peloso, G.M., Guiducci, C., Sougnez, C., Garimella, K.V., Fisher, S., Abreu, J., Barry, A.J., et al. (2010). Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. *N. Engl. J. Med.* 363, 2220–2227.
- Niewoehner, J., Bohrmann, B., Collin, L., Ulrich, E., Sade, H., Maier, P., Rueger, P., Stracke, J.O., Lau, W., Tissot, A.C., et al. (2014). Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. *Neuron* 81, 49–60.
- Nishimasu, H., Ran, F.A., Hsu, P.D., Konermann, S., Shehata, S.I., Dohmae, N., Ishitani, R., Zhang, F., and Nureki, O. (2014). Crystal structure of Cas9 in complex with guide RNA and target DNA. *Cell* 156, 935–949.
- Niu, Y., Shen, B., Cui, Y., Chen, Y., Wang, J., Wang, L., Kang, Y., Zhao, X., Si, W., Li, W., et al. (2014). Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. *Cell* 156, 836–843.
- Oh, B., Hwang, S., McLaughlin, J., Solter, D., and Knowles, B.B. (2000). Timely translation during the mouse oocyte-to-embryo transition. *Development* 127, 3795–3803.
- Pattanayak, V., Lin, S., Guilinger, J.P., Ma, E., Doudna, J.A., and Liu, D.R. (2013). High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. *Nat. Biotechnol.* 31, 839–843.
- Perez-Pinera, P., Kocak, D.D., Vockley, C.M., Adler, A.F., Kabadi, A.M., Polstein, L.R., Thakore, P.I., Glass, K.A., Ousterout, D.G., Leong, K.W., et al. (2013). RNA-guided gene activation by CRISPR-Cas9-based transcription factors. *Nat. Methods* 10, 973–976.
- Plessis, A., Perrin, A., Haber, J.E., and Dujon, B. (1992). Site-specific recombination determined by I-SceI, a mitochondrial group I intron-encoded endonuclease expressed in the yeast nucleus. *Genetics* 130, 451–460.
- Pourcel, C., Salvignol, G., and Vergnaud, G. (2005). CRISPR elements in *Yersinia pestis* acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. *Microbiology* 151, 653–663.
- Qi, L.S., Larson, M.H., Gilbert, L.A., Doudna, J.A., Weissman, J.S., Arkin, A.P., and Lim, W.A. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell* 152, 1173–1183.
- Quiberoni, A., Moineau, S., Rousseau, G.M., Reinheimer, J., and Ackermann, H.W. (2010). *Streptococcus thermophilus* bacteriophages. *Int. Dairy J.* 20, 657–664.
- Ran, F.A., Hsu, P.D., Lin, C.Y., Gootenberg, J.S., Konermann, S., Trevino, A.E., Scott, D.A., Inoue, A., Matoba, S., Zhang, Y., and Zhang, F. (2013). Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. *Cell* 154, 1380–1389.
- Rouet, P., Smih, F., and Jasin, M. (1994). Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. *Mol. Cell. Biol.* 14, 8096–8106.
- Rudin, N., Sugarman, E., and Haber, J.E. (1989). Genetic and physical analysis of double-strand break repair and recombination in *Saccharomyces cerevisiae*. *Genetics* 122, 519–534.
- Sander, J.D., and Joung, J.K. (2014). CRISPR-Cas systems for editing, regulating and targeting genomes. *Nat. Biotechnol.* 32, 347–355.
- Sander, J.D., Dahlborg, E.J., Goodwin, M.J., Cade, L., Zhang, F., Cifuentes, D., Curtin, S.J., Blackburn, J.S., Thibodeau-Beganny, S., Qi, Y., et al. (2011). Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). *Nat. Methods* 8, 67–69.
- Sapranaukas, R., Gasiunas, G., Fremaux, C., Barrangou, R., Horvath, P., and Siksnys, V. (2011). The *Streptococcus thermophilus* CRISPR/Cas system provides immunity in *Escherichia coli*. *Nucleic Acids Res.* 39, 9275–9282.
- Schwank, G., Koo, B.K., Sasselli, V., Dekkers, J.F., Heo, I., Demircan, T., Sasaki, N., Boymans, S., Cuppen, E., van der Ent, C.K., et al. (2013). Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. *Cell Stem Cell* 13, 653–658.
- Shah, S.A., Erdmann, S., Mojica, F.J., and Garrett, R.A. (2013). Protospacer recognition motifs: mixed identities and functional diversity. *RNA Biol.* 10, 891–899.
- Shalem, O., Sanjana, N.E., Hartenian, E., Shi, X., Scott, D.A., Mikkelsen, T.S., Heckl, D., Ebert, B.L., Root, D.E., Doench, J.G., and Zhang, F. (2014). Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science* 343, 84–87.
- Smith, J., Grizot, S., Arnould, S., Duclert, A., Epinat, J.C., Chames, P., Prieto, J., Redondo, P., Blanco, F.J., Bravo, J., et al. (2006). A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. *Nucleic Acids Res.* 34, e149.
- Sternberg, S.H., Redding, S., Jinek, M., Greene, E.C., and Doudna, J.A. (2014). DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. *Nature* 507, 62–67.
- Tang, T.H., Bachelier, J.P., Rozhdestvensky, T., Bortolin, M.L., Huber, H., Drungowski, M., Elge, T., Brosius, J., and Hüttenhofer, A. (2002). Identification of 86 candidates for small non-messenger RNAs from the archaeon *Archaeoglobus fulgidus*. *Proc. Natl. Acad. Sci. USA* 99, 7536–7541.
- Tebas, P., Stein, D., Tang, W.W., Frank, I., Wang, S.Q., Lee, G., Spratt, S.K., Surosky, R.T., Giedlin, M.A., Nichol, G., et al. (2014). Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. *N. Engl. J. Med.* 370, 901–910.
- Urnov, F.D., Miller, J.C., Lee, Y.L., Beausejour, C.M., Rock, J.M., Augustus, S., Jamieson, A.C., Porteus, M.H., Gregory, P.D., and Holmes, M.C. (2005). Highly efficient endogenous human gene correction using designed zinc-finger nucleases. *Nature* 435, 646–651.

- Wang, H., Yang, H., Shivalila, C.S., Dawlaty, M.M., Cheng, A.W., Zhang, F., and Jaenisch, R. (2013). One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. *Cell* 153, 910–918.
- Wang, T., Wei, J.J., Sabatini, D.M., and Lander, E.S. (2014). Genetic screens in human cells using the CRISPR-Cas9 system. *Science* 343, 80–84.
- Wu, Y., Liang, D., Wang, Y., Bai, M., Tang, W., Bao, S., Yan, Z., Li, D., and Li, J. (2013). Correction of a genetic disease in mouse via use of CRISPR-Cas9. *Cell Stem Cell* 13, 659–662.
- Wu, X., Scott, D.A., Kriz, A.J., Chiu, A.C., Hsu, P.D., Dadon, D.B., Cheng, A.W., Trevino, A.E., Konermann, S., Chen, S., et al. (2014). Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. *Nature Biotechnol.* Published online Apr 20, 2014. <http://dx.doi.org/10.1038/nbt.2889>.
- Xu, G.L., and Bestor, T.H. (1997). Cytosine methylation targetted to pre-determined sequences. *Nat. Genet.* 17, 376–378.
- Yang, H., Wang, H., Shivalila, C.S., Cheng, A.W., Shi, L., and Jaenisch, R. (2013). One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. *Cell* 154, 1370–1379.
- Yin, H., Xue, W., Chen, S., Bogorad, R.L., Benedetti, E., Grompe, M., Kotliansky, V., Sharp, P.A., Jacks, T., and Anderson, D.G. (2014). Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. *Nature Biotechnol.* Published online Mar 30, 2014. <http://dx.doi.org/10.1038/nbt.2884>.
- Zahradka, K., Slade, D., Bailone, A., Sommer, S., Aeverbeck, D., Petranovic, M., Lindner, A.B., and Radman, M. (2006). Reassembly of shattered chromosomes in *Deinococcus radiodurans*. *Nature* 443, 569–573.
- Zhang, Y., Heidrich, N., Ampattu, B.J., Gunderson, C.W., Seifert, H.S., Schoen, C., Vogel, J., and Sontheimer, E.J. (2013). Processing-independent CRISPR RNAs limit natural transformation in *Neisseria meningitidis*. *Mol. Cell* 50, 488–503.